News MEI Pharma, Inc. Deutsche Boerse AG

Equities

MMI0

US55279B3015

Delayed Deutsche Boerse AG Other stock markets 11:43:00 18/04/2023 am IST			5-day change	1st Jan Change
4.2 ^EUR	-17.32%		-.--%	-.--%

09/05	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
11/04	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/05	BU
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	10/05	BU
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	10/05	CI
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	12/04	AQ
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04	BU
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	11/04	BU
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	11/04	CI
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04	CI
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04	BU
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03	BU
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03	CI
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	15/02	BU
Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	14/02	MT
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	14/02	BU
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02	CI
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	17/01	BU
MEI Pharma : Change in Certifying Accountants - Form 8-K	27/12	PU
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/12	BU
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	11/12	BU
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	11/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MEI Pharma, Inc. Deutsche Boerse AG

Equities

MMI0

US55279B3015

Summary

Filters